New antibody injection could ease bulging eyes in thyroid disease

NCT ID NCT06989918

Recruiting now Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests MHB018A, an antibody injection, against placebo in 108 people with active moderate-to-severe thyroid eye disease. Participants receive six injections over 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 mm without worsening the other eye.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MHB018A (a humanized antibody targeting IGF-1 receptor)
What this could lead to: If successful, this could provide a new treatment option to reduce eye bulging and inflammation in people with active thyroid eye disease.
What could go wrong: This is a relatively small Phase 3 trial (108 participants), and the drug may not work better than placebo. Possible side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID ASSOCIATED OPHTHALMOPATHIES

Contacts and locations

Locations

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 201419, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.